IMPACT OF TREATMENT ADMINISTRATION ON SELECTION OF BCR-ABL1 KINASE DOMAIN MUTATIONS

被引：0
|
作者：
Razga, F. [1 ]
Jurcek, T. [1 ]
Zackova, D. [1 ]
Dvorakova, D. [1 ,2 ]
Toskova, M. [1 ]
Jeziskova, I. [1 ]
Mayer, J. [1 ,2 ]
Racil, Z. [1 ,2 ]
机构：
[1] Univ Hosp Brno, Brno, Czech Republic
[2] Masaryk Univ Brno, CEITEC, Brno, Czech Republic
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1326
引用
收藏
页码：536 / 537
页数：2
相关论文
共 50 条
  • [21] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
  • [22] The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
    Parker, Wendy T.
    Yeung, David T. O.
    Yeoman, Alexandra L.
    Altamura, Haley K.
    Jamison, Bronte A.
    Field, Chani R.
    Hodgson, J. Graeme
    Lustgarten, Stephanie
    Rivera, Victor M.
    Hughes, Timothy P.
    Branford, Susan
    BLOOD, 2016, 127 (15) : 1870 - 1880
  • [23] Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
    Fominykh, Mikhail
    Shuvaev, Vasily
    Martynkevich, Irina
    Shukhov, Oleg
    Chelysheva, Ekaterina
    Turkina, Anna G.
    Abdulkadyrov, Kudrat
    BLOOD, 2016, 128 (22)
  • [24] Dynamics and Characteristics of BCR-ABL1 Multiple Mutations in Tyrosine Kinase Inhibitor Resistant CML
    Kim, Soo-Hyun
    Choi, Soo Young
    Lee, Sung-Eun
    Bang, Ju-Hee
    Byeun, Ji-Young
    Park, Jin-Eok
    Jeon, Hye-Rim
    Jang, Eun-Jung
    Jootar, Saengsuree
    Kim, Dong-Wook
    BLOOD, 2012, 120 (21)
  • [25] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
    Takeuchi, Asako
    Kondo, Toshinori
    Tasaka, Taizo
    Yamada, Seiko
    Hirose, Tadashi
    Fukuda, Hirofumi
    Shimizu, Risa
    Matsuhashi, Yoshiko
    Kondo, Eisei
    Wada, Hideho
    LEUKEMIA RESEARCH REPORTS, 2021, 15
  • [26] Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
    Soverini, Simona
    Branford, Susan
    Nicolini, Franck E.
    Talpaz, Moshe
    Deininger, Michael W. N.
    Martinelli, Giovanni
    Mueller, Martin C.
    Radich, Jerald P.
    Shah, Neil P.
    LEUKEMIA RESEARCH, 2014, 38 (01) : 10 - 20
  • [27] Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Malik, Sara
    Hassan, Shahzeb
    Eskazan, Ahmet Emre
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (11) : 975 - 978
  • [28] Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype
    Jiang, Xiaoyan
    Grant, Hannah
    Stebbing, Justin
    Foroni, Letizia
    Craddock, Charles
    Griffiths, Mike
    Clark, Richard E.
    O'Brien, Stephen
    Khorashad, Jamshid S.
    Gerrard, Gareth
    Wang, Lihui
    Irving, Julie
    Wang, Meng
    Karran, Loraine
    Dyer, Martin J. S.
    Forrest, Donna L.
    Page, Karen
    Eaves, Connie J.
    Woolfson, Adrian
    BLOOD, 2010, 116 (21) : 1390 - 1391
  • [29] BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
    Parker, W. T.
    Yeoman, A. L.
    Jamison, B. A.
    Yeung, D. T.
    Scott, H. S.
    Hughes, T. P.
    Branford, S.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1593 - 1598
  • [30] BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
    W T Parker
    A L Yeoman
    B A Jamison
    D T Yeung
    H S Scott
    T P Hughes
    S Branford
    British Journal of Cancer, 2013, 109 : 1593 - 1598
12345